{"info":{"title":{"content":"2024 CSCO指南重磅更新，洛拉替尼獲ALK陽性晚期NSCLC一線治療“I級優先推薦”","en":"2024 CSCO Guidelines Update, Lorlatinib Receives \"Level I Priority Recommendation\" for First-line Treatment of ALK-Positive Advanced NSCLC"},"description":{"content":"*僅供醫學專業人士閱讀參考2024CSCO指南更新，洛拉替尼獲得ALK陽性晚期NSCLC一線治療\"I級優先推薦\"。為積極...","en":"*For medical professionals only, for reference to the 2024 CSCO guideline update, lorlatinib has been awarded a \"Level I Priority Recommendation\" for the first-line treatment of ALK-positive advanced NSCLC. For the positive..."}},"items":[]}
